Wednesday, July 8, 2026

pharma · T Cell Lymphoma · Diabetes Mellitus · CRSP

S.A

S.A clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

San Lorenzo, EU HQ
2011 Founded
50 Employees
Public company Type
CRSP · NYSE Ticker
Company details
Status
Public
HQ
San Lorenzo, EU
Founded
2011
Employees
50
Programs
14
Drugs
8
Patents
65
Intelligence · Clinical Programs

S.A projects

7 ClinicalTrials.gov programs sponsored by S.A.

S.A has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. CTX112

    S.A.

    SLE (Systemic Lupus)

    phase 1 mab active

    1 trial
  2. CTX120

    S.A.

    Multiple Myeloma

    phase 1 mab terminated

    1 trial
  3. CTX130

    S.A.

    Renal Cell Carcinoma

    phase 1 mab terminated

    1 trial
  4. CTX130

    S.A.

    T Cell Lymphoma

    phase 1 mab terminated

    1 trial
  5. CTX310

    S.A.

    Cardiovascular

    phase 1 small molecule active

    1 trial
  6. VCTX210A unit

    S.A.

    Diabetes Mellitus

    phase 1 other completed

    1 trial
  7. VCTX211

    S.A.

    Diabetes Mellitus

    phase 1 other terminated

    1 trial

Frequently asked questions

How many clinical projects does S.A have?

7 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.